VaxGen vaccine trial fails the test but may offer insights.
The first AIDS vaccine to complete human trials showed disappointing results, even as VaxGen pledges to go forward with more studies. While researchers were encouraged by preliminary data showing that the antibody response to the vaccine offered some protection, AIDS groups criticized the company for putting a positive spin on the findings.
D016915:AIDS Vaccines / Q000627:therapeutic use*; D001741:Black or African American; D001213:Asian; D017277:Drug Approval / Q000331:legislation & jurisprudence; D005260:Female; D015658:HIV Infections / Q000208:ethnology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D010919:Placebos; D012309:Risk-Taking; D012725:Sexual Behavior; D014481:United States; D014486:United States Food and Drug Administration
D016915:AIDS Vaccines; C112734:AIDSVAX; D010919:Placebos